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Peptides in medicine 
Peptides have long been heralded as promising molecules for the treatment and 
management of a variety of disease states including cancer, diabetes and inflammatory 
disease [1]. They represent the interface between naturally occurring biologics and 
chemically synthesised active pharmaceutical ingredients, offering high selectivity for 
molecular targets, leading to increased therapeutic efficacy and lower capacity for side 
effects. Their widespread implementation throughout medicine has been limited by their 
relatively expensive cost of manufacture and poor bioavailability. Despite these challenges 
researchers, clinicians and the pharmaceutical industry continue to work together in an 
attempt to clinically translate peptides of therapeutic value. Issues relating to ease and cost 
of synthesis can be remedied by creating ultrashort peptide pharmacophores, composed of 
seven or less amino acids, which retain pharmacological properties of larger peptides and 
proteins. Short peptides are more attractive to the pharmaceutical industry as it is cheaper to 
scale-up their manufacture and they are more likely to be clinically translated for the benefit 
of patients. The area of peptidomimetics, including beta-peptides [2], D-enantiomeric 
variants [3] and peptoids [4], has resulted in a wealth of unnatural peptide-like structures 
which demonstrate improved stability profiles. Their success is exemplified by orally active 
angiotensin-converting-enzyme inhibitors (ACE inhibitors), for example captopril, widely 
prescribed for the treatment of hypertension and congestive heart failure since the early 
1980s [5]. 
 
Peptides as antimicrobials  
Peptides potential as antimicrobial therapies stem from their role as mediators of the innate 
immune response, serving as important weapons in nature and increasingly medicine for 
combating infection and controlling the host response to pathogens [6]. Their promise lies in 
not only in their ability to provide direct antimicrobial action via a variety of extracellular and 
intracellular targets but they also have the potential to harness the body’s own defences, 
utilising the ubiquitous properties peptides possess throughout nature, to prevent infection. 
This is demonstrated by the use of peptides as immune adjuvants in vaccine development, 
replacing components with questionable safety such as aluminium [7]. Traditional 
antimicrobials are susceptible to resistance development due to targeting of specific 
microbial receptors or biomolecular mechanisms [8]. There is an urgent need to develop the 
next generation of antimicrobial therapies, which act using several mechanisms, to limit 
induction of drug resistance and address the challenge of multidrug resistance. Serious 
concerns exist regarding increased antimicrobial resistance and the relative lack of new 
antimicrobials in development [9]. Peptides are not completely devoid of resistance 
development with recent reports of colistin’s reduced efficacy in China [10] and the 
elucidation of the two-component systems PhoP/PhoQ and PmrA/PmrB pathways which 
result in cationic modification of the membrane bound anchor lipid A by UDP-4-amino-4-
deoxy-L-arabinose, leading to increased bacterial resistance to cationic antimicrobial 
peptides and polymyxins [6, 11]. Despite such reports peptides still serve as promising 
molecules to fill the current void in antimicrobial drug development. Due to toxicity and 
stability concerns their marketed indications have been limited to the treatment of skin and 
tissue infections, although a variety of new routes of administration are forthcoming as 
exemplified by daptomycin, licensed in the United States as an intravenous therapy for right-
sided endocarditis [12]. Researchers continue to explore a variety of new peptide templates 
for improved antimicrobial efficacy, reduced toxicity, and greater microbial specificity, 
harnessing the power of molecular modelling and structure activity relationships to guide the 
design of unique amino acid sequences [13]. An increasingly exciting field of research 
involves the development of peptide-based nanomaterials which can be designed from the 
“bottom-up” to display optimal functional and pharmacological characteristics for their 
intended use  
 
Peptides as nanomaterial therapeutics 
Just as peptides can be tailored to demonstrate antimicrobial characteristics, their structure 
can be modified to enable them to assemble spontaneously into highly defined 
nanostructures. These self-assembling peptides are composed of amino acid building blocks 
which organise, via intermolecular interactions, into nanomaterial structures in response to 
physiological stimuli including: pH, temperature, ionic strength, and the presence of specific 
enzymes [14]. By modifying the amino acid sequence we can control whether these peptides 
assemble into hydrogels composed of nanofibers or peptide nanotube structures. Their 
responsiveness to changing physiological stimuli makes them promising platforms 
throughout the drug delivery and biomaterial fields. The properties that dictate a peptide’s 
ability to self-assemble are very similar to the principles that govern the activity of 
antimicrobial peptides, most significant of which is the hydrophobic:hydrophilic/charge 
balance of the peptide primary sequence [14]. Therefore researchers are able to control not 
only the process of self-assembly in response to stimuli but also pharmacological properties 
such as antimicrobial activity. In this way biofunctional nanomaterials can be designed and 
developed for specific functional requirements. These platforms have huge potential within 
infection treatment and prevention. Peptides are ideal materials for medical applications as 
they can be designed to demonstrate inherent biocompatibility, antimicrobial activity, 
biodegradability and possess numerous chemical groups which can be utilized to tailor 
functional properties (e.g. mechanical strength, stability, hydrogel formation). They have 
many advantages over current synthetic materials used in healthcare. Peptides possess vast 
chemical versatility due to the varying nature of their amino acid R-group. This is proven by 
how they are harnessed throughout nature. They can be utilised to create materials with very 
specific functionalities and with the potential to attach a variety of molecules including drugs 
[15].  As amino acids represent the building blocks of peptide, proteins and tissues they exist 
throughout the body possessing enhanced biocompatibility compared to synthetic based 
polymeric and nanomaterial systems. The amino acid sequence can also be altered to tailor 
biodegradation to specific requirements and release conjugated drug molecules for improved 
efficacy. Biologically derived peptides are proteins, from animals and plants, have been 
studied extensively for use as medical materials (e.g. collagen, silk) [16, 17]. However their 
use is limited as they require expensive post modification to both purify and tailor mechanical 
and biological properties to their clinical purpose. 
 
Future peptide nanomaterial technologies 
Self-assembling peptide materials demonstrate significant potential for clinical translation as 
evidenced by the examples of octreotide which has been recently granted regulatory 
approval as a therapy for acromegaly [1]. Both peptide hydrogel and nanotube platforms 
have a variety of potential clinical applications in the antimicrobial field. Their most obvious 
use is as a hydrogel wound therapy given peptides form the building blocks of tissues and 
skin. Peptides can be manufactured within the laboratory to reproduce the unique 
mechanical and biological properties of natural tissue, with the potential to provide both 
antimicrobial and anti-inflammatory action [15]. Peptide hydrogels can represent the next 
generation of medical device coatings, triggered to respond to infection development via 
pathogenic stimuli (e.g. specific bacterial enzymes) thereby providing prolonged protection 
from bacterial attachment and biofilm formation [18, 19]. An easy to synthesise low 
molecular weight peptide has the potential to widely be exploited as immune adjuvants for 
vaccines, 3D cell culture, cell and bioactive molecule (e.g. genes) delivery, bioimaging 
agents and diagnostics. Peptide nanotube platforms have huge potential as drug delivery 
platforms for transversing biological barriers, for example the outer membrane of Gram-
negative bacteria, mimicking the value of their carbon counterparts in terms of therapeutic 
applications but with improved chemical functionality for drug conjugation and reduced 
toxicity concerns [20]. Their value may lie in encapsulating and extending the spectrum of 
activity of licensed Gram-positive selective antibiotics for delivery across the outer 
membrane of Gram-negative bacteria including Pseudomonas aeruginosa, Escherichia coli, 
Klebsiella pneumoniae and Acinetobacter baumannii. This membrane is a major physical 
barrier to the entry of antibiotics in Gram-negative infection and a significant contributor to 
antimicrobial resistance. There is a serious lack of available, effective narrow spectrum 
Gram-negative selective antibiotics in development. Our research group are currently 
assessing if nanotubes have the added ability to extend the spectrum of activity of current 
Gram-positive selective antibiotics and deliver them across the lipopolysaccharide outer 
membrane barrier, providing synergistic action. Using existing, licensed antibiotics should 
prove advantageous in limiting the regulatory barriers and time to clinical translation, an 
important consideration in the fight against the increasing menace of antimicrobial 
resistance.   
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